Zentalis Pharmaceuticals Inc. announced the completion of enrollment in Part 2a of its Phase 2 DENALI clinical trial evaluating azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer $(PROC)$. Dose confirmation from Part 2a is expected in the first half of 2026, with a topline readout from DENALI Part 2 anticipated by year end 2026. The company indicated that positive results could support a potential accelerated approval, pending FDA feedback. Zentalis also plans to initiate the ASPENOVA Phase 3 confirmatory trial in the first half of 2026, comparing azenosertib to standard-of-care chemotherapy. As of September 30, 2025, Zentalis reported cash, cash equivalents, and marketable securities of $280.7 million, projecting financial runway into late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620411) on January 06, 2026, and is solely responsible for the information contained therein.